 This is an open label, single arm, and multicenter study. The study will include the following phases. A screening phase which lasts for 4 weeks to determine patient eligibility. This phase will be followed by a 24 week Open label treatment phase. The study treatment is defined as deferasirox 20mgkg BID 9Twice a day. Serum Ferritin Levels and MRI Magmetic Resonance Imaging LIC Liver Iron Concentration will be measured to evaluate the response to BID. 